uploads/2018/02/Sutent.png

Pfizer’s Sutent Generated Higher Revenues in 4Q17

By

Updated

Sutent’s revenue trends

Pfizer’s (PFE) Sutent generated revenues of $276 million in 4Q17, which reflected ~1% growth on a YoY (year-over-year) basis. In 4Q17, Sutent’s quarter-over-quarter revenues remained flat.

In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively—compared to $98 million and $174 million in 4Q16.

In emerging markets in 4Q17, Sutent reported revenues of $64 million, which reflected ~10% growth on a YoY basis.

In fiscal 2017, Sutent generated revenues of $1.08 billion, which reflected a 1% decline on a YoY basis. In 2017, in the US and international markets, Sutent generated revenues of $374 million and $707 million, respectively—compared to $391 million and $704 million in 2016.

In emerging markets in 2017, Sutent generated revenues of $262 million, which reflected ~8% growth on a YoY basis.

Article continues below advertisement

Recent developments

In November 2017, the FDA approved label expansion of Pfizer’s Sutent to use the drug as an adjuvant treatment of adults with an increased risk of developing recurrent renal cell carcinoma after nephrectomy.

The FDA approved Sutent’s label expansion based on the results of the S-TRAC trial. The S-TRAC trial included patients with a high risk of renal cell carcinoma recurrence. When the patients were administered Sutent, there was a significant reduction in the risk of disease-free survival and tumor recurrence compared to patients receiving a placebo as adjuvant therapy.

In the marketplace, Sutent competes with Novartis’s (NVS) Gleevec, Bayer’s (BAYZF) Nexavar, and Exelixis’s (EXEL) Cabometyx.

Advertisement

More From Market Realist